Alto Neuroscience

Biopharma IPOs From the First Half of 2024
BioSpace
Thu, 05/30/24 - 11:17 am
IPOs
biotewch
CG Oncology
Kyverna Therapeutics
ArriVent Biopharma
Alto Neuroscience
Contineum Therapeutics
Boundless Bio
Fractyl Health
Metagenomi
Telomir
Rapport Therapeutics
Telix Pharmaceuticals
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Brain drug developer Alto Neuroscience prices $129M IPO
BioPharma Dive
Fri, 02/2/24 - 11:39 am
Alto Neuroscience
IPOs
CNS
CNS disorder biotech Alto Neuroscience sets terms for $101 million IPO
Renaissance Capital
Mon, 01/29/24 - 11:12 am
Alto Neuroscience
IPOs
biomarkers
depression schizophrenia
2024 Brings Surprising Early Surge of Biotech IPOs
BioSpace
Fri, 01/19/24 - 09:43 am
biotech
IPOs
CG Oncology
Alto Neuroscience
ArriVent Biopharma
Kyverna Therapeutics
Metagenomi
Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Fierce Biotech
Tue, 01/16/24 - 09:54 am
Alto Neuroscience
machine learning
artificial intelligence
IPOs
depression
Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win
BioSpace
Tue, 12/5/23 - 09:55 am
Alto Neuroscience
ALTO-300
major depressive disorder
clinical trials
Eli Lilly supports Alto Neuroscience in $45m Series C round
Clinical Trials Arena
Wed, 11/22/23 - 11:30 am
Eli Lilly
Alto Neuroscience
funding
psychiatric diesase
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety